Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
2.520
-0.030 (-1.18%)
Apr 7, 2025, 3:59 PM EDT - Market closed

Vivos Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Net Income
-11.14-13.58-23.85-20.29-12.06
Upgrade
Depreciation & Amortization
0.580.620.670.730.72
Upgrade
Loss (Gain) From Sale of Assets
--0.04--
Upgrade
Stock-Based Compensation
0.791.843.112.912.66
Upgrade
Other Operating Activities
0.01-3.69-1.270.883.43
Upgrade
Change in Accounts Receivable
-0.230.260.750.23-0.56
Upgrade
Change in Accounts Payable
-1.050.730.490.14-0.27
Upgrade
Change in Unearned Revenue
-1.43-0.610.64-0.54-0.01
Upgrade
Change in Other Net Operating Assets
-0.232.49-0.160.20.41
Upgrade
Operating Cash Flow
-12.69-11.95-19.59-15.74-5.68
Upgrade
Capital Expenditures
-0.57-0.85-0.92-2.4-0.12
Upgrade
Cash Acquisitions
----0.23-
Upgrade
Other Investing Activities
---0.01-
Upgrade
Investing Cash Flow
-0.57-0.85-0.92-2.61-0.12
Upgrade
Long-Term Debt Issued
----1.27
Upgrade
Long-Term Debt Repaid
----0.03-0.08
Upgrade
Net Debt Issued (Repaid)
----0.031.19
Upgrade
Issuance of Common Stock
19.2412-27.9322.29
Upgrade
Other Financing Activities
-1.36-1.08--2.24-0.25
Upgrade
Financing Cash Flow
17.8810.92-24.1723.54
Upgrade
Net Cash Flow
4.62-1.88-20.515.8217.74
Upgrade
Free Cash Flow
-13.26-12.8-20.51-18.13-5.8
Upgrade
Free Cash Flow Margin
-88.21%-92.74%-128.00%-107.38%-44.39%
Upgrade
Free Cash Flow Per Share
-2.64-10.50-22.28-21.35-11.27
Upgrade
Cash Interest Paid
---0.020.03
Upgrade
Levered Free Cash Flow
-9.68-7.69-11.25-11.27-2.83
Upgrade
Unlevered Free Cash Flow
-9.68-7.69-11.25-11.26-2.77
Upgrade
Change in Net Working Capital
2.71-1.51-1.540.340.58
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q